Roche Has Busy 2027 Ahead

Dow Jones10-22

1045 GMT - Roche Holding's late-stage pipeline includes some overlooked medicines and the Swiss drugmaker looks set to have a busy 2027 with clinical updates, analysts at Bank of America say in a research note. The company's third-quarter update offered a peek at clinical-trial results due next year, which include late-stage studies for inflammatory bowel disease ulcerative colitis, hemophilia A and lymphoma. Those medicines could add to a pipeline of new medicines that the company aims to launch over the next year, with breast-cancer drug giredestrant as its key asset, according to Bank of America. But multiple-sclerosis drug fenebrutinib and lung-cancer medicine divarasib are overlooked opportunities that might eclipse any debate on Roche's base business, the analysts say. Shares fall 0.3%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment